Key facts
- KLISBio’s last known valuation is $34.9M (Dec 2022).
- It has raised $27.3M; the latest was Later Stage VC ($15.7M) in Jan 2025.
- Notable investors include European Innovation Council, CDP Venture Capital (Rome), Primo Capital (Milano), Anya Capital, Enea Tech e Biomedical — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for KLISBio
- ·The full record, as it builds
Funding rounds
No funding rounds for KLISBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KLISBio
Developer of an innovative medical technology designed to find new tissue regeneration methods. The company's technology offers silk-based bio-materials that help to regenerate human tissues, including those present in the vascular system, and then to degrade and be safely absorbed in the body, enabling medical research companies to develop products harnessing the power of nano-fibers and use them for the treatment of tissue-related diseases.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2014
- Employees
- 21
- Website
- klis.bio/
- Ownership
- Privately Held (backing)
KLISBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KLISBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KLISBio in its N-PORT filings yet. We sweep new filings monthly.